Cheri WalkerVP M&A North America

Merrill Lynch Global Pharmaceutical,

Biotechnology and Medical Device Conference

New York, February 8, 2006

W W W . Q I A G E N . C O MSlide: 2

Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

Forward Looking Statements

W W W . Q I A G E N . C O MSlide: 3

New developments in DNA forensicsApr 22nd 2004

CRAIG HARMAN was drunk when, in May 2003, he killed Michael Little by throwing a brick from a motorway overpass. He had neither motive nor connection to the victim, meaning that, under normal circumstances, his crime would have been almost impossible to solve…

QIAGEN Technologies in the News

January 7, 2006

From Roger Boyesin Salzburg

DNA solves the 250-year mystery of Mozart's skullMUSEUM staff in Salzburg refused for years to go near the case displaying the skull that had reputedly housed the brain of Wolfgang Amadeus Mozart.

GERM SENSORS

Money & Investing

By Peter Kang

02.13.06 Bird flu and bioterrorism threats are creating healthy opportunities for outfits that sniff out lethal bugs.

PRIVACY MATTERS By Jane Black

JUNE 26, 2003

Whose DNA Is It Anyway?Asking convicted felons to surrender their genetic privacy is one thing. TAKING `ROOTS' TO A DNA LEVEL

January 29, 2006

The chairman of Harvard University's Department of African and African-American Studies has just produced a four-part series for PBS, "African American Lives," in which DNA testing is used to trace the African ancestry of nine famous Americans.

W W W . Q I A G E N . C O MSlide: 4

Purification of Complex Biological Samples

DNADNASample PrepSample PrepBloodBlood

Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin,

W W W . Q I A G E N . C O MSlide: 5

Multiple QIAGEN Product Dimensions

Nucleic Acids/Genetic Information

Assays/ApplicationsBiological Samples

W W W . Q I A G E N . C O MSlide: 6

QIAGEN’s Leadership

Focus and innovation

Leading market share and penetration

Science-driven culture

Brand excellence

Standard-setting technologies

Growing leadership in MDx

Strong and deep partnerships

W W W . Q I A G E N . C O MSlide: 7

A Global Company

Total Employees: 1599

Americas< 50% of Sales: Sales/Marketing Force: 210Low-teens growth in 2005

EuropeApprox 40% of SalesSales/ Marketing Force: 270Low-teens growth in 2005

AsiaApprox 10% of SalesSales /Marketing Force: 50Low-teens growth in 2005

W W W . Q I A G E N . C O MSlide: 8

Markets by Customer

Academia 45%

Mkt. growth 5-7%

PharmaBiotech

35%Mkt. growth

7-9%

Applied Testing

>1%Mkt. growth

20-30%

Molecular Testing

20%Mkt. growth

20-30%

Life Science Research

Academic Research

Solid in most countries

US solid

Europe strong

Japan still underperforms, outlook stronger

Pharma/Biotech Research

Strong in US, softer in EU

Key account management successful

Applied Testing

Still small - but accelerating growth rates

Molecular Diagnostics

Direct sales strong growth, outlook strong

OEM sales still off target

W W W . Q I A G E N . C O MSlide: 9

Life Science Growth Drivers

Collection Stabilization Homogenisation Lysis Purification

Preanalytical Standardization

Cloning

Sequencing

Gene Expression

Arrays

Real Time PCR

Genotyping

DNA, RNA Assays

Mouse Knock-outs

PCR

Multiplex Assays

Bacteria

Blood

Viruses

Tissue

Swabs

Yeasts

Stool

Urine

Hair

Saliva

Standardized analytes

Standardized analytes

W W W . Q I A G E N . C O MSlide: 10

Life Science Research Market Leadership

Mar

ket s

hare

100%

Home Brew

Competitors

Preanalytical Technologies

Highest market share

Large and growing market

Continue to penetrate

Strong brand

Sales leadership

Standard-setting technologies

Strong IP portfolio

Significant barriers to entry

Stable, cash generating business

QIAGEN SETS THE STANDARD!QIAGEN SETS THE STANDARD!

W W W . Q I A G E N . C O MSlide: 11

Applied Testing Markets

Source: company estimates, various industry research reports

Food Pathogens

Food GMO

BioSecurity

QC PharmaPharmacogen.

Veterinarian

Human ID

Estimated market: >US$ 500 million (2008)

W W W . Q I A G E N . C O MSlide: 12

Total Diagnostics Markets

Molecular Diagnostics

6%

Diabetes Care21%

Other IVD23%

Clinical Chemistry

14%

Immunochem25%

Near Patient Testing

11%

Source: company estimates for 2006, various industry research reports

$2 B Market

W W W . Q I A G E N . C O MSlide: 13

QIAGEN – a Leader in Molecular Diagnostics

Oncology 11%

Blood Banks/Other

25%

Genetic Testing 13%

Viral infections 39%

Non-Viral Infections

12%

Estimated market:> US$ 2 billion (2006)

Source: company estimates, various industry research reports

RocheGenprobeQIAGENBayerAbbottDigeneOthers .

W W W . Q I A G E N . C O MSlide: 14

QIAGEN MDx Strategy Evolution

Expanding portfolio of assays

Artus acquisition

PG Biotech acquisition

Setting standards in preanalytical solutions

Linking with tests (assays)

CE and FDA regulated products

Numerous strategic alliances

Impressive new product pipeline

More than 20 assay developers

>12 new assays to come in next 4 months

W W W . Q I A G E N . C O MSlide: 15

QIAGEN Real Time PCR Assays

CMV LC CECMV RG CECMV TM CEHSV 1/2 RG CEHSV 1/2 TM AbbottHHV 6 LC CEHHV 6 RG CEVZV RG CEC. pneumoniae TM CEC. pneumoniae RG CECandida RG CEAspergillus RG CEInfluenza LC CEM. pneumoniae LC CERSV LC CEAdenovirus LC CEB. pertussis LC CEEnterovirus LC CEEnterovirus RG CEEnterovirus TM AbbottL. pneumophila LC CEL. pneumophila RG CEMTB diff LC RUOMTB diff RG RUO

C. pneumoniae LC CEParainfluenza LC CEBorrelia LC CEHAV LC RocheHAV TM AbbottNorovirus LC CEWNV TM ASRInfluenza RG CERSV RG CEAdenovirus RG CEB. pertussis RG CEM. pneumoniae RG CENorovirus RG CEParainfluenza RG CEMTB diff TM CEB. pertussis RG CEC. trachomatis PLUS TM CEC. trachomatis PLUS TM LCC. trachomatis PLUS TM RGHCV LC CEHCV RG CEHIV-1 RNA RG CEGeneral bacteria detectionHHV-6 TM Abbott

L. pneumophila TM AbbottMalaria diff QC LCM. paratuberculosis LC CEM. diff LC CEM. diff TMM. diff RGHemachromatosis LC CEFactor II/V C LC CEDengue RGHTLV LCInfluenza TML. pneumophila TM AbbottMalaria diff QC LCM. paratuberculosis LC CEM. diff LC CEM. diff TMM. diff RGHemachromatosis LC CEFactor II/V C LC CEDengue RGHTLV LCInfluenza TM

Representative but not complete list

W W W . Q I A G E N . C O MSlide: 16

Shenzhen PG Biotech

sFDA approved to sell qPCR diagnostic kits

GMP manufacturing plant certified by SFDA for extrinsic diagnostic reagent in China

Only manufacturer in China possessing certificates for HIV, HCV and HBV necessary for blood banking testing

First company approved for PCR-based avian flu test for veterinarian and quarantine testing

US$ 6-7 million in 2006 (>1 million assays!)

Expect to close in 1Q06

W W W . Q I A G E N . C O MSlide: 17

The Total MDx Solution

Applied Biosystems

Abbott Laboratories

Roche Diagnostics

Applied Biosystems

Roche Applied Science

Bio-Rad, Stratagene

Cepheid

Molecular DiagnosticsLife Science Research

Mirrored Capabilities

Open ArchitectureDetection Instrument

PCR Assay

PreAnalyticalSolution

W W W . Q I A G E N . C O MSlide: 18

Molecular Diagnostics Growth Strategy

OEM Devel.

5%

OEM Sales15%

Direct Sales 80%

Direct Sales

Growing direct sales force > 40

No instrument dependency

Focus on pathogens

Market leader is developing countries

OEM Products

Integrated solutions

Assays, preanalytical, automation

> 15 Partners

>100 clinical trials using QIAGEN

> 50 clinical trials using PreAnalytiX

OEM development

Developing solutions for partners

W W W . Q I A G E N . C O MSlide: 19

Executing on the Acquisition Strategy

Core Markets:Standardization &

Integration

Core Markets:Standardization &

Integration

Expand Markets:Establish New Standards

Expand Markets:Establish New StandardsNew Markets:

DisseminationNew Markets:Dissemination

3

1

Discovery Clinical phases

Plasmid

Cells

2

gDNA

RNA

Molecular Diagnostics

Applied Markets

Academic research

BiomedicalResearch

Pharma

Personalized Medicine

Proteins

Routine use

W W W . Q I A G E N . C O MSlide: 20

Alliance of Leaders

Alliance of leadersBrings together two strongest brands and product lines of the industry in sample management.

Linking portfoliosLinks complementary technology portfolios and expertise through co-marketing andco-development projects.

Technology resourceCreates options to develop products based on the unique expertise of both partners.

StandardizationFocuses on improving biological sample management through fully compatible products.

W W W . Q I A G E N . C O MSlide: 21

Long History of Revenue Growth

0

50

100

150

200

250

300

350

400

450

2000 2001 2002 2003 2004 2005E*

*Midpoint of guidance for 2005*Midpoint of guidance for 2005

5 year CAGR = 19%5 year CAGR = 19%$ mill.

W W W . Q I A G E N . C O MSlide: 22

* excluding acquisition, restructuring, integration and related charges as well as amortization on acquired IP

66% 70%

27% 28%

16% 19%

Gross Margin Operating Margin* Net Income Margin*

Q3 2004

Q3 2005

Highly Profitable Business Model

W W W . Q I A G E N . C O MSlide: 23

$ 205.6211.1Cash on Balance Sheet

-0.060.13Cash EPS in US$ per share

-11.416.6Free cash flow

2.72.6Capital expenditures

-8.719.2Operating cash flow

-26.5-4.7Working capital & others5.26.3D&A

12.617.6Net income

Q3 04Q3 05In US$ millions unless indicated

Free cash flow computed using cash from operations less capital expendituresCash EPS computed using cash from operations divided by number of fully diluted shares

Operating cash flow margin of 19%

QIAGEN Generates Significant Cash Flow

W W W . Q I A G E N . C O MSlide: 24

Guidance

0.44 – 0.470.320.32EPS (US$)1

25% - 26%25%25%Operating margin1

405 - 407298.7294.1Revenues

(mio US$)

GuidanceNov 8, 2005*

CER to guidance*9M 2005

* based on foreign exchange rates used for guidance communicated on February 15, 20051 excluding acquisition, restructuring, integration and related charges

Already achieved in Q3 2005

EPS as guided Feb 2005

W W W . Q I A G E N . C O MSlide: 25

Cash generating, stable core business

Highest market share

Industry leading growth

Industry standard setter

Proven innovation engine

Shaping the MDx market

MDx springboard for future growth

Transactions for catalytic growth

Key Investment Considerations